Invitation to presentation of Recipharm’s interim report for the third quarter 2017 on the 9th November

Recipharm will publish its interim report for January-September 2017 on 9 November at 07:45 am CET.

The company invites investors, analysts and media to a web conference (in English) on 9 November at 10:00 am CET, where CEO Thomas Eldered and CFO Henrik Stenqvist will present and comment on the report as well as answer questions.

The report will be available on Recipharm’s website www.recipharm.com/investor-relations from 07:45 am CET the same day and the presentation from the webcast will be uploaded during the day on the 9 November.

To participate in the web conference, please use the below link:

http://edge.media-server.com/m/p/s9iighaa  

Questions may be submitted by dialing below telephone numbers or by typing them in the Q&A box during the conference. If you don’t wish to ask questions by telephone you only need to participate through the link above.

From Sweden: +46 8 566 426 51
From Denmark: +45 354 455 77
From Norway: +47 235 00 243
From the UK: +44 333 300 08 04
From Germany: +49 691 380 34 30
From Switzerland: +41 225 809 034
From France: + 33 170 750 711
From Portugal: +351 210 609 105
From India: +91 226 187 51 27
From Italy: +39 023 601 38 21
From Israel: +972 372 076 79
From the USA: +1 631 913 14 22 

Pin code for participants:
78642485#

For more information, please contact:
ir@recipharm.com , telephone: +46 8 602 52 00

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden,  Telephone  +46 8 602 52 00

www.recipharm.com

Tags:

About Us

About RecipharmRecipharm is a leading CDMO (Contract Development and Manufacturing Organisation) in the pharmaceutical industry employing some 5 000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from Big Pharma to smaller research- and development companies. Recipharm’s turnover is approximately SEK 5.3 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm. For more information on Recipharm and our services, please visit www.recipharm.com